Clinical efficacy and safety of cerivastatin: Summary of pivotal phase IIb/III studies

American Journal of Cardiology

Volumn 82, Issue 4 B, 1998, Pages 32J-39J

  Davignon, Jean ^a   Hanefeld, Markolf ^b   Nakaya, Noriaki ^b   Hunninghake, Donald B ^b   Insull Jr, William ^b   Ose, Leiv ^b  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ANGINA PECTORIS; BACKACHE; BRONCHITIS; CATARACT; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPOLIPEMIA; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT INFECTION;

EID: 0032572673     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00435-4     Document Type: Conference Paper

References (24)

1. Kannel W.B., Castelli W.P., Gordon T., McNamara P.M. Serum cholesterol, lipoproteins and the risk of coronary heart disease. The Framingham Study. Ann Intern Med. 74:1971;1-12.
2. Castelli W.P., Wilson P.W.F., Levy D., Anderson K. Serum lipids and risk of coronary artery disease. Atherscler Rev. 21:1990;7-19.
3. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
4. Jones P.H. Practical approaches to treatment strategies in dyslipidemias. A clinical overview of dyslipidemias treatment strategies . Am J Med. 93:1992;187-198.
5. Frohlich J., Brun L.D., Blank D., Campeau L., Crockford P., Curnew G., Dafoe W., Davignon J., Dufour R., Emery G., Fergusson J., Filipchuk N., Gagné C., Hayden M.R., Langlois S., Leiter L., Lerman S., Lupien P.-J., Ma P., McPherson R., McQueen M., Mishkel M., Montigny M., Nakhle G., Ooi T.T., Roederer G., Roleau J.-L., Roy M., Seccombe D., Sniderman A.D., DuSouich P., Steiner G., Vlahos W.D., Xhignesse M., Yokoyama S. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia. Can J Cardiol. 9:1993;405-412.
6. Blum C.B. Comparison of the properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol. 73:(suppl):1994;3D-11D.
7. Nawrocki J.W., Weiss S.R., Davidson M.H., Sprecher D.L., Schwartz S.L., Lupien P.-J., Jones P.H., Haber H.E., Black D.M. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 15:1995;678-682.
8. Davignon J., Montigny M., Dufour R. HMG-CoA reductase inhibitors a look back and a look ahead . Can J Cardiol. 8:1992;843-864.
9. Angerbauer R., Bischoff H., Steinke W., Ritter W. BAY w 6228 hypolipidemic HMG-CoA reductase inhibitor . Drugs Fut. 19:1994;537-541.
10. Frey R., Mazzu A.L., Ritter W., Heller A.H., Kuhlmann J. Safety and tolerability of rivastatin, a novel HMG-CoA reductase inhibitor, in phase-I single dose studies. (Abstr.) Naunyn Schmiedebergs Arch Pharmacol. 33:(suppl):1993;120.
11. Mazzu A.L., Lettieri J., Kaiser L., Frey R., Heller A.H. Ascending multiple dose safety, tolerability and pharmacodynamics of rivastatin in humans. (Abstr. No.PIII-95) Clin Pharmacol Ther. 53:1993;230.
12. Data on file, Bayer USA. Study No. D96039.
13. Stein E.A., Sprecher D., Allenby K.S., Tosiello R.L., Whalen E., Ripa S.R. Cerivastatin, a new potent HMG-CoA reductase inhibitor efficacy and tolerability in primary hypercholesterolemia . J Cardiovasc Pharmacol Ther. 2:1997;7-16.
14. Insull W., Stein E.A., Whalen E., Ripa S. Cerivastatin, a new potent HMG-CoA reductase inhibitor efficacy and tolerability in primary hypercholesterolemia . (Abstr.) J Am Coll Cardiol. 29:(suppl A):1997;46A.
15. Insull W, Stein EA, Ripa S, Whalen E, and the Cerivastatin Study Group. Long term safety and efficacy of cerivastatin, a potent new HMG-CoA reductase inhibitor effective at ultra-low doses. Poster presented at the XIII International Symposium on Drugs Affecting Lipid Metabolism, Florence, Italy, May 31, 1998.
16. Hsu I., Spinler S.A., Johnson N.E. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmaco Ther. 29:1995;743-759.
17. Stein EA, Isaacsohn J, Stoltz R, Mazzu AL, Liu MC, Lane C, Heller AH. Efficacy and safety of 0.8 mg dosage of cerivastatin, a novel HMG-CoA reductase inhibitor. (Abstr. 254470) 47th Scientific Session of the American College of Cardiology, 1998.
18. Lintott C.J., Scott R.S., Sutherland W.H.F., Bremer J. Treating hypercholesterolemia with HMG-CoA reductase inhibitors a direct comparison of simvastatin anand pravastatin . Aust NZ J Med. 23:1993;381-386.
19. Lea A.P., McTavish D. Atorvastatin a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias . Drugs. 53:1997;828-847.
20. Bakker-Arkema R.G., Davidson M.H., Goldstein R.J., Davignon J., Isaacsohn J.L., Weiss S.R., Keilson L.M., Brown W.V., Miller V.T., Shurzinske L.J., Black D.M. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 275:1996;128-133.
21. Fruchart J.C., Ailhaud G. Apolipoprotein A-containing lipoprotein particles physiological role, quantification and clinical significance . Clin Chem. 38:1992;793-799.
22. Illingworth D.R., Bacon S.P., Larsen K.K. Long-term experience with HMG-CoA reductase inhibitors in the therapy of hypercholesterolemia. Atheroscler Rev. 18:1988;161-187.
23. Boccuzzi S.J., Thomas S., Bocanegra J., Walker F., Shapiro D.R., Keegan M.E. Long-term safety and efficacy profile of simvastatin. Am J Cardiol. 68:1991;1127-1131.
24. Dujovne C.A., Chremos A.N., Pool J.L., Schapner H., Bradford R.H., Shear C.L., Higgins J., Dowton M., Franklin F.A., Nash D.T., Gould A.L., Langendörfer A. Expanded clinical evaluation of lovastatin (EXCEL) study results. IV. Additional perspectives on the tolerability of lovastatin. Am J Med. 91:(suppl):1991;25S-30S.